Art

J-GLOBAL ID：201702249218556044   Reference number：17A1557247

A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban

ピリドン誘導体はホスホランバンの阻害作用を減弱することによりSERCA2aを活性化する【Powered by NICT】

Author (13)： Kaneko Manami (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Yamamoto Hisato (Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan) ,  Sakai Hiroki (Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan) ,  Kamada Yusuke (Biomolecular Research Laboratories, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Tanaka Toshiki (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Fujiwara Shuji (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Yamamoto Syunsuke (Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Takahagi Hiroki (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Igawa Hideyuki (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Kasai Shizuo (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Noda Masakuni (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan) ,  Inui Makoto (Department of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan) ,  Nishimoto Tomoyuki (Cardiovascular and Metabolic Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan)
Material： European Journal of Pharmacology  (Eur J Pharmacol)
Volume： 814  Page： 1-8  Publication year： 2017 
JST Material Number： B0841A  ISSN： 0014-2999  CODEN： EJPHAZ  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： The cardiac sarco/endoplasmic ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1557247&from=J-GLOBAL&jstjournalNo=B0841A") }}

Thesaurus term： in vitro experiment ,  ATPase ,  therapy ,  Heart ,  Cardiac Myocyte ,  interaction ,  Sarcoplasmic Reticulum ,  Membrane Proteins ,  *Endoplasmic Reticulum ,  isolation (separation) ,  skeletal muscle ,  cardiac insufficiency ,  *sarcoplasmic reticulum calcium ATPase ,  *SERCA2a ,  alicyclic compound ,  fatty acid ,  lactone ,  olefin compound ,  unsaturated carboxylic acid ,  polyol

Author keywords (5)： Sarco/endoplasmic reticulum Ca²⁺-dependent ATPase 2a ,  Phospholamban ,  Ca²⁺ handling ,  Inotropic effect ,  Lusitropic effect

JST classification (3)： Bioactive peptides  (EB08100U) ,  Basic research of pharmacology of crude drugs  (GX06020J) ,  Basic research of sympathomimetics  (GW05022H)

Substance index (1)： Thapsigargin

Terms in the title (6)： ピリドン誘導体 ,  ホスホランバン ,  阻害作用 ,  減弱 ,  SERCA2a ,  活性化